COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

BioCentury’s roundup of preclinical news

Emory, UNC to test nucleoside analog against COVID-19

The Emory Institute for Drug Development and University of North Carolina at Chapel Hill are conducting preclinical studies of nucleoside analog to treat COVID-19, an Emory University spokesperson told BioCentury. EIDD-2801, which is slated to enter the clinic in April for flu, has the same mechanism of action as remdesivir from Gilead Sciences Inc. (NASDAQ:GILD). Reported in December in Journal of Virology, EIDD-2801’s

Read the full 708 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE